Indivior Pharmaceuticals, Inc. (INDV) Stock Price & How to Invest

Indivior is a specialty pharmaceutical company that develops and markets treatments for opioid use disorder (OUD) and related conditions. Its flagship product, SUBLOCADE, is a once-monthly long-acting injectable form of buprenorphine that has become the dominant long-acting injectable (LAI) for OUD in the United States, holding roughly a 76% share of that market. The company also sells the sublingual film SUBOXONE (now facing generic competition), the opioid overdose reversal agent OPVEE (nalmefene nasal spray), and PERSERIS for schizophrenia. Indivior historically listed in London but shifted its primary listing to the Nasdaq, and it trades under the ticker INDV.

The investment picture is now defined by concentration, transition, and a merger. SUBLOCADE drives the large majority of growth: Q1 2026 SUBLOCADE net revenue was roughly $232 million (up about 32% year over year), and in Q2 2026 total revenue reached about $343 million with net income of about $122 million and EPS of $1.15 against a $0.92 consensus, after which management raised full-year 2026 guidance again. Over the last twelve months revenue was about $1.33 billion and net income about $356 million. On August 3, 2026 Indivior and Supernus Pharmaceuticals agreed to an all-stock merger of equals: each Supernus share converts into 1.5401 Indivior shares, Indivior holders end up with about 56.5% of the combined company, and the company is renamed Supernus, Inc., trading on Nasdaq as SUPN and led by Supernus CEO Jack Khattar. Before closing, Indivior holders receive a one-time special dividend of $1.0 billion in total ($8.13 per share, record date October 30, 2026), funded partly by a $650 million term loan. The combined company targets about $2.2 billion of pro forma revenue across 11 CNS medicines and $125 million of annual cost synergies. As of October 16, 2026 INDV closed near $32.86 for a market capitalization of roughly $3.9 billion, down about 8% year to date but up about 33% over the past year.

Indivior is highly concentrated in a single product, so any slowdown in SUBLOCADE adoption, pricing pressure, or competitive entry (for example from Alkermes VIVITROL or Camurus and Braeburn's BRIXADI) would weigh heavily on the whole company. The Supernus merger adds its own risks: it may not close if either stockholder vote or another condition fails (in which case the $8.13 special dividend is not paid), integration and the $125 million synergy target may disappoint, and the combined company takes on a $650 million term loan to help fund the $1.0 billion dividend, for pro forma net debt of about $878 million. The stock fell about 19% over the three months to mid-October 2026 as the market weighed these issues. Legacy SUBOXONE film revenue continues to erode as generics take share, and the company has a long history of antitrust and opioid-related litigation and settlements that can resurface as financial and reputational overhangs. Reliance on government and Medicaid channels exposes revenue to reimbursement and budget shifts. Pipeline setbacks, such as the decision to halt INDV-6001 Phase 3, show that non-core bets may not deliver. As a specialty pharma, it also faces regulatory, patent, and manufacturing risks common to the sector.

4 analysts publish price targets on INDV, averaging $49.00 against a $32.45 price as of October 2026, or +51.0%. The published targets run from $43.00 to $53.00, a narrow spread, and the ratings split 4 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full INDV forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Indivior Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. SUBLOCADE market leadership and expansion. SUBLOCADE is the clear leader in long-acting injectable treatment for opioid use disorder, with roughly a 76% U.S. The most optimistic published target, $53.00, assumes this works close to its best case.

The case against. Indivior is highly concentrated in a single product, so any slowdown in SUBLOCADE adoption, pricing pressure, or competitive entry (for example from Alkermes VIVITROL or Camurus and Braeburn's BRIXADI) would weigh heavily on the whole company. The most pessimistic target, $43.00, is roughly what INDV is worth if this bites instead.

Read the full bull and bear case on INDV, including what would have to change to break either one. Walnut is not an investment adviser.

No. Indivior Pharmaceuticals, Inc. (INDV) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Indivior Pharmaceuticals, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.33B
• Q2 2026 revenue: ~$343M (up ~14% YoY)
• Net income (TTM): ~$356M (EPS ~$2.79)
• Margins (gross / operating): ~86% / ~47%
• P/E: ~11.8x trailing, ~6.7x forward
• Market cap: ~$3.9B
• Special dividend (merger-contingent): $8.13 per share

Indivior trades as a profitable mid-cap specialty pharma at about 11.8x trailing and 6.7x forward earnings and roughly 2.9x sales, a lower multiple than in mid-2026 after a pullback of nearly 19% over three months. The $8.13 special dividend, payable only if the Supernus merger closes, equals about a quarter of the October 16 share price, so post-dividend shares will represent a stake in the combined Supernus, Inc. Analysts expect 2026 EPS of about $4.41 and 2027 EPS of about $4.88 on a standalone basis.

Other names that sit close to INDV: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get INDV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so INDV sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where INDV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

INDV has been a single-product growth story built on SUBLOCADE, and the pending Supernus merger turns it into a diversified CNS company with about $2.2 billion of pro forma revenue. The shares are down about 8% YTD (up about 33% over a year), so the open questions are SUBLOCADE's growth, merger execution, and the extra debt taken on to fund the special dividend.

Whether INDV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is INDV a buy or a sell?, and where the stock could go from here in the INDV stock forecast.

For income investors, whether INDV pays a dividend and how the payout looks is covered in does INDV pay a dividend? And to weigh INDV against a peer, read the full side-by-side comparisons: INDV vs ALKS and INDV vs CNS.